The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target

被引:107
作者
Cromm, Philipp M. [1 ]
Crews, Craig M. [1 ,2 ,3 ]
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA
[2] Yale Univ, Dept Chem, New Haven, CT 06511 USA
[3] Yale Univ, Dept Pharmacol, New Haven, CT 06511 USA
基金
美国国家卫生研究院;
关键词
20S PROTEASOME; CRYSTAL-STRUCTURE; MULTIPLE-MYELOMA; IRREVERSIBLE INHIBITOR; SELECTIVE-INHIBITION; PRECLINICAL MODELS; SALINOSPORAMIDE-A; EMERGING ROLE; UBIQUITIN; IMMUNOPROTEASOME;
D O I
10.1021/acscentsci.7b00252
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
As the central figure of the cellular protein degradation machinery, the proteasome is critical for cell survival. Having been extensively targeted for inhibition, the constitutive proteasome has proven its role as a highly valuable drug target. However, recent advances in the protein homeostasis field suggest that additional chapters can be added to this successful story. For example, selective immunoproteasome inhibition promises high clinical efficacy for autoimmune disorders and inflammation, and proteasome inhibitors might serve as novel therapeutics for malaria or other microorganisms. Furthermore, utilizing the destructive force of the proteasome for selective degradation of essential drivers of human disorders has opened up a new and exciting area of drug discovery. Thus, the field of proteasome drug discovery still holds exciting questions to be answered and does not simply end with inhibiting the constitutive proteasome.
引用
收藏
页码:830 / 838
页数:9
相关论文
共 83 条
[1]   The proteasome: A suitable antineoplastic target [J].
Adams, J .
NATURE REVIEWS CANCER, 2004, 4 (05) :349-360
[2]   The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention? [J].
Aminake, Makoah Nigel ;
Arndt, Hans-Dieter ;
Pradel, Gabriele .
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE, 2012, 2 :1-10
[3]   The immunoproteasome in antigen processing and other immunological functions [J].
Basler, Michael ;
Kirk, Christopher J. ;
Groettrup, Marcus .
CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (01) :74-80
[4]   Regulated protein turnover: snapshots of the proteasome in action [J].
Bhattacharyya, Sucharita ;
Yu, Houqing ;
Mim, Carsten ;
Matouschek, Andreas .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2014, 15 (02) :122-133
[5]   A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma [J].
Chauhan, Dharminder ;
Singh, Ajita V. ;
Aujay, Monette ;
Kirk, Christopher J. ;
Bandi, Madhavi ;
Ciccarelli, Bryan ;
Raje, Noopur ;
Richardson, Paul ;
Anderson, Kenneth C. .
BLOOD, 2010, 116 (23) :4906-4915
[6]   Structure and functions of the 20S and 26S proteasomes [J].
Coux, O ;
Tanaka, K ;
Goldberg, AL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1996, 65 :801-847
[7]   Proteasome inhibitors in cancer therapy [J].
Crawford, Lisa J. ;
Walker, Brian ;
Irvine, Alexandra E. .
JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2011, 5 (02) :101-110
[8]   Targeted Protein Degradation: from Chemical Biology to Drug Discovery [J].
Cromm, Philipp M. ;
Crews, Craig M. .
CELL CHEMICAL BIOLOGY, 2017, 24 (09) :1181-1190
[9]   Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome [J].
Cui, Haissi ;
Baur, Regina ;
Le Chapelain, Camille ;
Dubiella, Christian ;
Heinemeyer, Wolfgang ;
Huber, Eva M. ;
Groll, Michael .
CHEMBIOCHEM, 2017, 18 (06) :523-526
[10]   The Proteasome Inhibitor Epoxomicin Has Potent Plasmodium falciparum Gametocytocidal Activity [J].
Czesny, Beata ;
Goshu, Samrawit ;
Cook, James L. ;
Williamson, Kim C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) :4080-4085